Ra-223 dichloride management in a Nuclear Medicine Unit: experience of a referral institution
Journal of Radiology and Oncology · 2017
DOI: 10.29328/journal.jro.1001010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Radiology and Oncology, 2017. Verfasst von Giulia Anna Follacchio und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ra-223 dichloride is a first-in-class alpha-emitting radiopharmaceutical recently introduced into clinical practice for treatment of men with Castration-Resistant Prostate Cancer (CRPC) and symptomatic bone metastases. Due to the proven benefit on Overall Survival and the favorable toxicity profile, Ra-223 therapy is gaining widespread use in both US and Europe. In this article, we describe the routinary management of patients undergoing Ra-223 treatment in our Institution. Currently, Ra-223 therapy is indicated for 6 intravenous injections (55 kBq per kg of body weight) administered every 28 days. In comparison to other radiopharmaceuticals, Ra-223 handling and administration do not need any additional training for authorized users. Due to the minimal external dose rate emission, Ra-223 dichloride can be delivered in an outpatient setting. Moreover, no particular precautions other than standard hygiene measures must be taken by patients’ family members or caregivers. Ra-223 therapy is associated to a favorable hematologic toxicity profile, while non-hematologic adverse events are generally mild and easy to manage. Given the favorable toxicity profile of this treatment, clinical trials are currently ongoing to evaluate efficacy and safety of Ra-223 treatment in combination or sequence with recently approved drugs such as abiraterone acetate, enzalutamide and sipuleucel-T. In addition, the recent interest in Ra-223 bone lesion dosimetry could open the way to a dosimetric-based therapeutic approach with Ra-223. In this new scenario, results of these promising clinical trials may help clarifying the optimal sequencing of new therapeutic possibilities for metastatic CRPC and the appropriate eligibility criteria for Ra-223 treatment in oncologic patients.
Zitieren
APA
Follacchio, G. A., Frantellizzi, V., Monteleone, F., Vincentis, G. D., & Liberatore, M. (2017). Ra-223 dichloride management in a Nuclear Medicine Unit: experience of a referral institution. Journal of Radiology and Oncology. https://doi.org/10.29328/journal.jro.1001010
Vancouver
Follacchio GA, Frantellizzi V, Monteleone F, Vincentis GD, Liberatore M. Ra-223 dichloride management in a Nuclear Medicine Unit: experience of a referral institution. Journal of Radiology and Oncology. 2017. doi:10.29328/journal.jro.1001010
BibTeX
@article{Follacchio2017,
author = {Follacchio, Giulia Anna and Frantellizzi, Viviana and Monteleone, Francesco and Vincentis, Giuseppe De and Liberatore, Mauro},
title = {Ra-223 dichloride management in a Nuclear Medicine Unit: experience of a referral institution},
journal = {Journal of Radiology and Oncology},
year = {2017},
doi = {10.29328/journal.jro.1001010}
}
EUVIMED